Which statement best characterizes the tolerability of CGRP monoclonal antibodies?

Which statement best characterizes the tolerability of CGRP monoclonal antibodies?

• A. They are generally well tolerated.
• B. They cause severe liver toxicity in most patients.
• C. They routinely cause kidney stones.
• D. They must be used with daily insulin therapy.

Answer: (A)

The key idea is that CGRP monoclonal antibodies have a favorable safety profile and are generally well tolerated. These antibodies act specifically on CGRP or its receptor, which limits off-target effects and systemic exposure. In clinical trials, their adverse effects are usually mild, with the most common being injection-site reactions. There is no strong signal for liver toxicity or kidney stones, and they do not require concurrent daily insulin therapy. Their large-molecule nature and limited metabolism contribute to fewer drug interactions and a steady safety profile, supporting the characterization as generally well tolerated.

The key idea is that CGRP monoclonal antibodies have a favorable safety profile and are generally well tolerated. These antibodies act specifically on CGRP or its receptor, which limits off-target effects and systemic exposure. In clinical trials, their adverse effects are usually mild, with the most common being injection-site reactions. There is no strong signal for liver toxicity or kidney stones, and they do not require concurrent daily insulin therapy. Their large-molecule nature and limited metabolism contribute to fewer drug interactions and a steady safety profile, supporting the characterization as generally well tolerated.